Financial Performance - Nanjing Pharmaceutical reported a total revenue of 27.967 billion yuan for the first half of 2025, an increase of 2.7% year-on-year [1] - The net profit attributable to shareholders was 291 million yuan, a decrease of 6.44% compared to the previous year [1] - In Q2 2025, total revenue reached 13.721 billion yuan, up 3.32% year-on-year, while net profit dropped by 25.17% to 114 million yuan [1] Profitability Metrics - The gross margin was 5.91%, down 4.08% year-on-year, and the net margin was 1.36%, a decline of 6.99% [1] - The total of selling, administrative, and financial expenses was 1.007 billion yuan, accounting for 3.6% of revenue, a decrease of 5.4% year-on-year [1] - Earnings per share (EPS) decreased by 7.5% to 0.22 yuan, while operating cash flow per share was -3.08 yuan, down 71.41% [1] Asset and Debt Management - Cash and cash equivalents decreased by 6.34% to 2.306 billion yuan, while accounts receivable increased by 16.21% to 16.948 billion yuan [1] - Interest-bearing liabilities decreased by 20.97% to 8.231 billion yuan, indicating improved debt management [1] - The company's return on invested capital (ROIC) was 7.08%, with a historical median of 8.11%, suggesting average capital returns [1][2] Business Model Insights - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying factors [2] - The cash flow situation is concerning, with cash assets only 7.19% of total assets and 18.3% of current liabilities [3] - The accounts receivable to profit ratio reached 2970.15%, indicating potential issues with cash collection [3]

Core Viewpoint - The company has released its 2025 semi-annual report, which includes details on financial performance, profit distribution, and the management of raised funds [3][9][30]. Group 1: Company Overview - The company is named Nanjing Pharmaceutical Co., Ltd., with stock code 600713 and bond code 110098 [5]. - The board of directors and supervisory board confirm the authenticity and completeness of the report [1][28]. Group 2: Financial Data - The company did not distribute profits during the reporting period, but plans to distribute a cash dividend of 1.70 yuan per 10 shares, totaling approximately 222.47 million yuan [3]. - The total amount raised from the issuance of convertible bonds was approximately 1.08 billion yuan, with a net amount of about 1.07 billion yuan after deducting issuance costs [13]. Group 3: Fund Management - As of June 30, 2025, the balance of the raised funds was approximately 124.10 million yuan [14]. - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations [15]. - The company has not used idle raised funds to temporarily supplement working capital [18]. Group 4: Board and Supervisory Meetings - The board of directors held its third meeting on August 28, 2025, where all proposals were approved unanimously [8][9]. - The supervisory board also approved the semi-annual report and the special report on the management of raised funds, with no dissenting votes [30][31].

证券日报网讯 8月29日晚间，南京医药发布公告称，2025年半年度公司实现营业收入27，967，411， 701.62元，同比增长2.70%；归属于上市公司股东的净利润为291，276，712.36元，同比下降6.44%。 （编辑 何成浩） ...

（文章来源：证券日报） 证券日报网讯 8月29日晚间，南京医药发布公告称，公司第十届董事会第三次会议审议通过了《南京医 药股份有限公司2025年半年度报告》及其摘要等多项议案。 ...

智通财经APP讯，南京医药(600713.SH)披露2025年半年度报告，报告期公司实现营收279.67亿元，同比 增长2.70%;归母净利润2.91亿元，同比下降6.44%;扣非净利润2.62亿元，同比下降14.08%;基本每股收益 0.222元。公司拟向全体股东每10股派发现金红利1.70元(含税)。 ...

（原标题：南京医药(600713.SH)发布半年度业绩，归母净利润2.91亿元，同比下降6.44%） 智通财经APP讯，南京医药(600713.SH)披露2025年半年度报告，报告期公司实现营收279.67亿元，同比 增长2.70%;归母净利润2.91亿元，同比下降6.44%;扣非净利润2.62亿元，同比下降14.08%;基本每股收益 0.222元。公司拟向全体股东每10股派发现金红利1.70元(含税)。 ...

证券日报网讯 8月29日晚间，南京医药发布公告称，公司第十届监事会第二次会议审议通过了《南京医 药股份有限公司2025年半年度报告》及其摘要等多项议案。 （文章来源：证券日报） ...

南京医药8月29日披露半年报，公司上半年实现营业收入279.67亿元，同比增长2.70%；归属于上市公司 股东的净利润2.91亿元，同比下降6.44%；基本每股收益0.222元/股。 ...

Core Insights - The pharmaceutical distribution market in China has shown steady growth, with a total sales scale exceeding 30 trillion yuan from 2019 to 2023, reflecting a year-on-year increase of 7.5% after excluding non-comparable factors [1][3]. Market Structure - The wholesale market dominates the pharmaceutical distribution sector, accounting for approximately 78% of the market share, while the retail market holds a 22% share [3]. Revenue Growth - The revenue of direct reporting pharmaceutical distribution enterprises reached 22,362 billion yuan in 2023, marking an 8% year-on-year increase after excluding non-comparable factors [5]. Accounts Receivable - The average accounts receivable days for pharmaceutical wholesale enterprises exceeded 150 days in 2023, with a reported average of 152 days, which is an increase of 2 days compared to 2022 [7]. Product Composition - Western medicine is the primary category in pharmaceutical sales, representing 68.7% of total sales, followed by traditional Chinese medicine at 15.5% and Chinese medicinal materials at 2.4%, collectively accounting for 86.6% of the market [9].

| 证券简称：南京医药 | 编号：ls2025-111 | | --- | --- | | 证券代码：600713 | | 二、监事会会议审议情况 1、审议通过《南京医药股份有限公司 2025 年半年度报告》及其摘要； 同意 3 票、反对 0 票、弃权 0 票 有关书面审核意见如下： 债券代码：110098 债券简称：南药转债 南京医药股份有限公司第十届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 监事会会议召开情况 南京医药股份有限公司（以下简称"公司"）第十届监事会第二次会议于 2025 年 8 月 15 日以电话及邮件方式发出会议通知及材料，并于 2025 年 8 月 28 日以现场加通讯方式在公司 14 楼 1403 会议室召开，会议召开符合《公司法》和 《公司章程》的规定。会议由监事会主席徐媛媛女士主持，应到会监事 3 人，实 到会监事 3 人，监事姚霞女士、杨庆女士现场出席了本次会议，监事会主席徐媛 媛女士以通讯方式出席了本次会议。会议经过充分讨论，以记名投票方式审 ...